BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van den Brom R, van Es S, Leliveld A, Gietema J, Hospers G, de Jong I, de Vries E, Oosting S. Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. Cancer Treatment Reviews 2016;46:63-72. [DOI: 10.1016/j.ctrv.2016.04.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Neuzillet Y, Albrand G, Caillet P, Paillaud E, Mongiat-Artus P. [Specificity of the management of metastatic renal cancer in the older patient]. Prog Urol 2019;29:874-95. [PMID: 31771770 DOI: 10.1016/j.purol.2019.08.272] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Fan AC, Leppert JT. In Search of Clinical Biomarkers of Response to Checkpoint Inhibitor Therapy in Renal Cell Carcinoma. JAMA Netw Open 2021;4:e2035120. [PMID: 33496791 DOI: 10.1001/jamanetworkopen.2020.35120] [Reference Citation Analysis]
3 Zaffuto E, Karakiewicz PI, Capitanio U. Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next? Ann Transl Med 2016;4:291. [PMID: 27568482 DOI: 10.21037/atm.2016.06.25] [Reference Citation Analysis]
4 Manseck A, Manseck S, Körner C. [Concepts in geriatric uro-oncology]. Urologe A 2019;58:403-9. [PMID: 30859232 DOI: 10.1007/s00120-019-0892-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Adv Ther 2017;34:2452-65. [PMID: 29076108 DOI: 10.1007/s12325-017-0628-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ali AK, Watson DE. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. Pharmacotherapy 2017;37:1383-90. [PMID: 28950039 DOI: 10.1002/phar.2035] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
7 Paterson C, Yew-Fung C, Sweeney C, Szewczyk-Bieda M, Lang S, Nabi G. Predictors of growth kinetics and outcomes in small renal masses (SRM ≤4 cm in size): Tayside Active Surveillance Cohort (TASC) Study. Eur J Surg Oncol 2017;43:1589-97. [PMID: 28365130 DOI: 10.1016/j.ejso.2017.03.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
8 Lalani AA, Bossé D, McGregor BA, Choueiri TK. Immunotherapy in the Elderly. Eur Urol Focus 2017;3:403-12. [PMID: 29183736 DOI: 10.1016/j.euf.2017.11.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
9 Wagener N. [Renal cell carcinoma in older and geriatric patients]. Urologe A 2017;56:1019-24. [PMID: 28451746 DOI: 10.1007/s00120-017-0396-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]